Based on each patient's genetic characteristics, it is able to propose the best combination of currently available cancer treatments. It personalizes care for each patient, estimating the five-year survival probability in each case. These types of technological developments are essential for achieving greater decision-making capacity in the healthcare system by supporting clinical decision-making. They make decisions more efficient, effective, and safer, thereby optimizing available resources and treatments. Not only at the time of treatment decision-making, but also at the time of diagnosis and throughout both processes. Implementation Initiatives Given the company's international nature, it is carrying out projects and initiatives in different countries, such as Colombia, where it is developing a project for the early diagnosis of breast and lung cancer in isolated populations; and Mexico, where it is launching the production of its artificial intelligence engines for the selection of personalized treatments for breast and lung cancer in one of the country's largest private hospital chains. In Spain, its implementation is being carried out through: - Presentation of the solution to oncology professionals who can benefit from it, by including it in their daily clinical practice. - Partnerships with service and technology companies that work in synergy to offer the healthcare sector more comprehensive solutions. - Partnerships with institutions and teams working in the field of Precision Medicine, whether through developmental or translational research. Along these lines, it is worth noting that Keyzell, in partnership with the Príncipe de Asturias Hospital in Madrid, has been awarded (in the pre-project phase) a PERTE grant for the development of artificial intelligence for hematologic oncology. This project will involve seven hospitals in Spain and other countries such as Mexico and France. - Commitment to the development and leadership of value-added projects in the Spanish healthcare system, benefiting from technology for better and more precise decision-making through artificial intelligence and machine learning. It is worth remembering that Keyzell's company has recently been honored by the 2022 International Life Science Awards from Global Health&Pharma and the 2022 Isaac Peral National Awards for Research, Science and Innovation, granted by the AEDEEC (Agricultural and Biotechnology Association). It has also been recognized by the British magazine "Health Tech World" as one of the 50 best innovative technology companies in the healthcare sector in 2022.